Multi-Specific Binding Molecules Evading Protein A and Sbi
Solution Overview
Problem
Current monoclonal antibody therapies for Staphylococcus aureus infections are ineffective due to protein A and Sbi binding, proteolytic degradation, and inability to neutralize leukotoxins, leading to limited protective immunity and treatment options.
Innovation Solution
Development of multi-specific binding molecules comprising a first binding domain that targets glycosylated staphylococcal surface proteins and a second binding domain that neutralizes staphylococcal leukotoxins, connected via a linker peptide, which are resistant to proteolytic degradation and evade protein A and Sbi binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody therapies are used to treat Staphylococcus aureus infections, then treatment options are provided, but the therapies are ineffective due to protein A and Sbi binding, proteolytic degradation, and inability to neutralize leukotoxins
Solution Approach 1:
The patent creates composite binding molecules that combine multiple functional domains: an antibody variable region for binding staphylococcal surface proteins, a Fibronectin type III (FN3) domain for neutralizing leukotoxins, and engineered resistance to protein A and Sbi binding. This composite structure integrates multiple protective and neutralizing functions into a single therapeutic agent, resolving the contradiction by making the therapy effective against multiple virulence mechanisms simultaneously.
Solution Approach 2:
The binding molecule is segmented into distinct functional domains: the antibody variable region (VH and VL domains) for recognizing and binding to glycosylated staphylococcal surface proteins, the FN3 domain for binding and neutralizing leukotoxins, and linker regions connecting these domains. This segmentation allows each domain to independently perform its specific function while contributing to the overall effectiveness of the therapeutic molecule.
2Reliability
If multi-specific binding molecules are developed to neutralize leukotoxins and evade protein A/Sbi binding, then protective immunity is enhanced, but the molecular complexity increases
Solution Approach 1:
The binding molecule is designed with multi-functionality: the antibody variable region provides binding to staphylococcal surface proteins, the FN3 domain provides leukotoxin neutralization, and the engineered structure provides resistance to protein A and Sbi binding. A single molecule thus performs multiple protective functions that would otherwise require separate therapeutic agents, enhancing protective immunity while managing complexity through functional integration.
Data Source
AI summary
The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.